Michael Saylor's company, Strategy, holds 849,327 Bitcoins valued at $64.44 billion, confirmed in a recent chart update. Despite the portfolio's size, no new Bitcoin purchases have been confirmed since early November, with the last acquisition of 811 BTC occurring between October 26 and November 1. The company's financing strategy involves preferred shares (STRC), which recently returned to a $100 price level, potentially enabling future Bitcoin purchases. Investors await further updates to see if Strategy resumes buying amid current market corrections.
Michael Saylor's Strategy company and its Bitcoin holdings provide context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 09, 2026 16:01 WIB: out of 50 major cryptocurrencies, 6 rose and 43 fell. Kusama (KSM) dropped 4.16% to Rp55.779, PancakeSwap (CAKE) fell 3.84% to Rp33.255 with a balanced buy-sell order activity, and Axie Infinity (AXS) declined 3.74% to Rp14.390 with 95% sell orders.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
